Internal Manufacturing Capabilities Are Critical To Level-Up eTheRNA
eTheRNA CEO Steven Powell On Growing The Biotech In The 2020s
A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.
You may also be interested in...
Steven Powell, chair of the board at Cambridge Cognition, talks about the group’s latest spin-off company, Monument Therapeutics.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.